Quantum-Si Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Retrieved on:
Monday, March 6, 2023
Science, Research, General Health, Health, Health Technology, Technology, Genetics, Semiconductor, Cloud, Molecule, Society, Protein, Arginine, Protein sequencing, Senior, PIN, VIB, Proteomics, HUPO, Acquisition, Platinum, Flemish, Disease, American Society of Human Genetics, IAB, Partnership, GAAP, Quantum, ASHG, Human Proteome Organization, Rationalization, EBITDA, Investment, Human genetics, Drug development, Conference, Biovista, Proteome, Dicarboxylic acid, Vlaams Instituut voor Biotechnologie, Cryptocurrency, Fine chemical, Management, Microscope, Pharmaceutical industry, Arms industry, Video game, Neuroscience
Selling, general and administrative expenses were $11.2 million in the fourth quarter of 2022, compared to $13.4 million in the fourth quarter of 2021.
Key Points:
- Selling, general and administrative expenses were $11.2 million in the fourth quarter of 2022, compared to $13.4 million in the fourth quarter of 2021.
- Net loss was $33.1 million in the fourth quarter of 2022, compared to a net loss of $29.4 million in the fourth quarter of 2021.
- Adjusted EBITDA was negative $24.5 million in the fourth quarter of 2022, compared to negative $20.4 million in the fourth quarter of 2021.
- Quantum-Si will host a conference call to discuss its fourth quarter and fiscal year 2022 financial results on Monday, March 6, 2023, at 8:30 AM Eastern Time (ET).